Citation: | ZHANG Jia-ling, GE Hui, WU Wen-juan. Diagnostic value of contrast-enhanced LI-RADS classification criteria in hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2021, 19(5): 833-837. doi: 10.16766/j.cnki.issn.1674-4152.001929 |
[1] |
安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-727.
|
[2] |
《原发性肝癌诊疗规范(2019年版)》编写专家委员会. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. doi: 10.3969/j.issn.1001-5256.2020.02.007
|
[3] |
卓涛, 陈海燕, 李坚, 等. 早期肝癌患者在临床诊断期间使用肝脏超声造影诊断其病灶位置和转移中的应用效果[J]. 中国超声医学杂志, 2020, 36(6): 528-531. doi: 10.3969/j.issn.1002-0101.2020.06.014
|
[4] |
杨丹, 李锐. 美国放射学院超声造影LI-RADS指南(2016版)[J]. 临床超声医学杂志, 2017, 19(10): 712-718. doi: 10.3969/j.issn.1008-6978.2017.10.027
|
[5] |
王延杰, 严昆, 高旭东, 等. 超声及超声造影诊断HCC的局限性[J]. 中国超声医学杂志, 2020, 36(6): 520-524. doi: 10.3969/j.issn.1002-0101.2020.06.012
|
[6] |
KONO Y, LYSHCHIK A, COSGROVE D, et al. Contrast enhanced ultrasound (CEUS)liver imaging reporting and data system (LI-RADS): the official version by the American college of radiology (ACR)[J]. Ultraschall Med, 2017, 38(1): 85-86. doi: 10.1055/s-0042-124369
|
[7] |
齐宝文, 吕娟, 张利. 血清学指标联合超声造影时间-强度曲线对肝脏肿瘤良恶性的鉴别诊断价值[J]. 中国医药, 2019, 14(10): 1527-1530. doi: 10.3760/j.issn.1673-4777.2019.10.021
|
[8] |
杨丹, 李锐, 郭燕丽, 等. 肝细胞癌分化程度、病灶大小及肝病背景对超声造影廓清过程的影响[J]. 中华医学超声杂志(电子版), 2016, 13(4): 286-292. doi: 10.3877/cma.j.issn.1672-6448.2016.04.011
|
[9] |
HEIMBACH J K, KULIK L M, FINN R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology (Baltimore, Md. ), 2018, 67(1): 358-380. doi: 10.1002/hep.29086
|
[10] |
PETER R G, ALEJANDRO F, JOSEP M L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. doi: 10.1016/j.jhep.2018.03.019
|
[11] |
TERZI E, IAVARONE M, POMPILI M, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules[J]. J Hepatol, 2018, 68(3): 485-492. doi: 10.1016/j.jhep.2017.11.007
|
[12] |
吴晓贝, 罗鸿昌, 李开艳, 等. 超声造影LI-RADS分类在肝细胞癌诊断中的应用价值[J]. 中华超声影像学杂志, 2018, 27(11): 936-941. doi: 10.3760/cma.j.issn.1004-4477.2018.11.004
|
[13] |
ELSAYES K M, FOWLER K J, CHERNYAK V, et al. User and system pitfalls in liver imaging with LI-RADS. [J]. J Magn Reson Imaging, 2019, 50(6): 1673-1686. doi: 10.1002/jmri.26839
|
[14] |
吴亚丽, 李丹, 毛雯. 超声检查在肝硬化背景下肝细胞肝癌中的诊断价值[J]. 癌症进展, 2019, 17(10): 1174-1177. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201910016.htm
|
[15] |
宋珂达, 李梓豪, 姜洪池. 肝内胆管细胞癌的诊疗进展[J]. 国际外科学杂志, 2020, 47(2): 112-117. https://www.cnki.com.cn/Article/CJFDTOTAL-JRFS201803022.htm
|
[16] |
YUAN M, LI R. Enhancement patterns of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: correlation with clinicopathologic findings and prognosis[J]. Ultrasound Med Biol, 2019, 45(1): 26-34. doi: 10.1016/j.ultrasmedbio.2018.08.014
|
[17] |
吴琴, 戴莹, 严昆, 等. 肝内胆管细胞癌超声造影增强模式及肝背景的影响[J]. 中国超声医学杂志, 2019, 35(7): 616-619. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCY201907014.htm
|
[18] |
LI F, LI Q, LIU Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017[J]. Eur Radiol, 2020, 30(1): 461-470. doi: 10.1007/s00330-019-06317-2
|